Revlimid

Active substance

lenalidomide

Holder

Celgene sprl

Status

Running

Indication

diffuse large B cell lymphoma in patients who already received at least two prior treatment lines

Public documents

Approbation

Information for the patient

Informed consent

Last update

31/07/2018

Last updated on 31/07/2018